ProMetic Life Sciences (OTCMKTS:PFSCF – Get Rating) and Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.
Valuation & Earnings
This table compares ProMetic Life Sciences and Syndax Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ProMetic Life Sciences||$36.55 million||3.49||-$150.73 million||N/A||N/A|
|Syndax Pharmaceuticals||$139.71 million||6.56||$24.93 million||$0.43||38.77|
Insider & Institutional Ownership
0.1% of ProMetic Life Sciences shares are owned by institutional investors. 6.3% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of current ratings and recommmendations for ProMetic Life Sciences and Syndax Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ProMetic Life Sciences||0||0||0||0||N/A|
Syndax Pharmaceuticals has a consensus price target of $29.75, suggesting a potential upside of 78.46%. Given Syndax Pharmaceuticals’ higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than ProMetic Life Sciences.
This table compares ProMetic Life Sciences and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ProMetic Life Sciences||-894.02%||-3,350.55%||-67.76%|
Volatility & Risk
ProMetic Life Sciences has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.
Syndax Pharmaceuticals beats ProMetic Life Sciences on 9 of the 11 factors compared between the two stocks.
ProMetic Life Sciences Company Profile (Get Rating)
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
Syndax Pharmaceuticals Company Profile (Get Rating)
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.